OA13092A - Constructs and methods for expression of recombinant HCV envelope proteins. - Google Patents

Constructs and methods for expression of recombinant HCV envelope proteins. Download PDF

Info

Publication number
OA13092A
OA13092A OA1200500194A OA1200500194A OA13092A OA 13092 A OA13092 A OA 13092A OA 1200500194 A OA1200500194 A OA 1200500194A OA 1200500194 A OA1200500194 A OA 1200500194A OA 13092 A OA13092 A OA 13092A
Authority
OA
OAPI
Prior art keywords
cell
protein
hcv
vector
host cell
Prior art date
Application number
OA1200500194A
Other languages
English (en)
Inventor
Erwin Sablon
Annie Van Broekhoven
Alfons Bosman
Erik Depla
Geert Deschamps
Original Assignee
Innogenetics Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innogenetics Nv filed Critical Innogenetics Nv
Publication of OA13092A publication Critical patent/OA13092A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08RNA viruses
    • C07K14/18Togaviridae; Flaviviridae
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5258Virus-like particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/50Fusion polypeptide containing protease site
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/24011Flaviviridae
    • C12N2770/24211Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/24011Flaviviridae
    • C12N2770/24211Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24223Virus like particles [VLP]

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
OA1200500194A 2001-04-24 2002-04-24 Constructs and methods for expression of recombinant HCV envelope proteins. OA13092A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01870088 2001-04-24

Publications (1)

Publication Number Publication Date
OA13092A true OA13092A (en) 2006-11-10

Family

ID=34072546

Family Applications (1)

Application Number Title Priority Date Filing Date
OA1200500194A OA13092A (en) 2001-04-24 2002-04-24 Constructs and methods for expression of recombinant HCV envelope proteins.

Country Status (20)

Country Link
US (3) US7314925B2 (pt)
EP (3) EP1414942A2 (pt)
JP (2) JP4173741B2 (pt)
KR (1) KR100950104B1 (pt)
CN (1) CN1636050A (pt)
AR (3) AR035869A1 (pt)
AU (3) AU2002308449B2 (pt)
BR (2) BR0209034A (pt)
CA (3) CA2443740A1 (pt)
CZ (1) CZ20032853A3 (pt)
HU (1) HUP0303924A2 (pt)
MX (2) MXPA03009632A (pt)
NZ (2) NZ529324A (pt)
OA (1) OA13092A (pt)
PL (1) PL366621A1 (pt)
RU (1) RU2274643C2 (pt)
SK (1) SK13142003A3 (pt)
WO (3) WO2002086100A2 (pt)
YU (1) YU84103A (pt)
ZA (3) ZA200308272B (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040185061A1 (en) * 1994-07-29 2004-09-23 Innogenetics N.V. Redox reversible HCV proteins with native-like conformation
CA2443740A1 (en) * 2001-04-24 2002-10-31 Innogenetics N.V. Constructs and methods for expression of recombinant hcv envelope proteins
DE10143490C2 (de) * 2001-09-05 2003-12-11 Gsf Forschungszentrum Umwelt Rekombinantes MVA mit der Fähigkeit zur Expression von HCV Struktur-Antigenen
JP2006516955A (ja) * 2002-11-08 2006-07-13 イノジェネティックス・ナムローゼ・フェンノートシャップ E1ペプチド及びns3ペプチドを含むhcvワクチン組成物
US7439042B2 (en) * 2002-12-16 2008-10-21 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
JP4371739B2 (ja) * 2003-09-02 2009-11-25 株式会社東芝 シリアルataインタフェースを持つ電子機器及びシリアルataバスのパワーセーブ方法
EP1602664A1 (en) * 2004-03-08 2005-12-07 Innogenetics N.V. HCV E1 comprising specific disulfide bridges
EP1574517A1 (en) * 2004-03-09 2005-09-14 Innogenetics N.V. HCV E1 comprising specific disulfide bridges
JP4885476B2 (ja) * 2004-05-21 2012-02-29 株式会社日本触媒 タンパク質及び/又はペプチドの細胞内導入方法
CN102614510A (zh) * 2004-10-18 2012-08-01 全球免疫股份有限公司 基于酵母的对慢性丙型肝炎感染的治疗
AU2011254055B2 (en) * 2004-10-18 2012-12-20 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
US20060234360A1 (en) * 2005-04-13 2006-10-19 Paola Branduardi Ascorbic acid production from D-glucose in yeast
US9216212B2 (en) * 2005-08-05 2015-12-22 University Of Massachusetts Virus-like particles as vaccines for paramyxovirus
US7951384B2 (en) * 2005-08-05 2011-05-31 University Of Massachusetts Virus-like particles as vaccines for paramyxovirus
AR058140A1 (es) * 2005-10-24 2008-01-23 Wyeth Corp Metodo de produccion proteica utilizando compuestos anti-senescencia
CA2651456A1 (en) * 2006-05-19 2007-11-29 Glycofi, Inc. Recombinant vectors
AU2015234338C1 (en) * 2006-07-28 2017-07-20 The Trustees Of The University Of Pennsylvania Improved vaccines and methods for using the same
JP5674310B2 (ja) * 2006-08-25 2015-02-25 ザ・マクファーレーン・バーネット・インスティテュート・フォー・メディカル・リサーチ・アンド・パブリック・ヘルス・リミテッド 組換えhcv e2糖タンパク質
JP2012503011A (ja) 2008-09-19 2012-02-02 グローブイミューン,インコーポレイテッド 慢性c型肝炎ウイルス感染の免疫療法
WO2010039224A2 (en) 2008-09-30 2010-04-08 University Of Massachusetts Medical School Respiratory syncytial virus (rsv) sequences for protein expression and vaccines
US20100104555A1 (en) * 2008-10-24 2010-04-29 The Scripps Research Institute HCV neutralizing epitopes
DE102009044224A1 (de) * 2009-10-09 2011-04-28 PomBio Tech GmbH Starterzentrum der Universität des Saarlandes Campus Geb. A1-1 Methode zur Produktion von HCV Virus-ähnlichen Partikeln
UY33821A (es) 2010-12-22 2012-07-31 Bayer Animal Health Gmbh Respuesta inmune potenciada en la especie bovina
WO2012145509A2 (en) 2011-04-19 2012-10-26 The Research Foundation Of State University Of New York Adeno-associated-virus rep sequences, vectors, and viruses
EP3590950A1 (en) 2011-05-09 2020-01-08 Ablynx NV Method for the production of immunoglobulin single varible domains
EP3110940A1 (en) 2014-02-28 2017-01-04 Bayer Animal Health GmbH Immunostimulatory plasmids
BR112018009653A2 (pt) * 2015-11-13 2018-11-13 Mammedov Tarlan produção de proteínas recombinantes n-deglicosiladas in vivo por co-expressão com endo h
EP3184642B1 (de) * 2015-12-22 2019-05-08 bisy e.U. Hefezelle
EP3515483A4 (en) 2016-09-21 2020-12-16 The Governors of the University of Alberta HEPATITIS C VIRUS IMMUNOGENIC COMPOSITIONS AND THEIR USE PROCEDURES

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4395395A (en) 1979-05-21 1983-07-26 The United States Of America As Represented By The Department Of Health And Human Services Detection of non-A, non-B hepatitis associated antigen
EP0288198A3 (en) * 1987-04-20 1989-03-29 Takeda Chemical Industries, Ltd. Production of peptide
US5135854A (en) 1987-10-29 1992-08-04 Zymogenetics, Inc. Methods of regulating protein glycosylation
US5350671A (en) 1987-11-18 1994-09-27 Chiron Corporation HCV immunoassays employing C domain antigens
US5698390A (en) 1987-11-18 1997-12-16 Chiron Corporation Hepatitis C immunoassays
US5683864A (en) 1987-11-18 1997-11-04 Chiron Corporation Combinations of hepatitis C virus (HCV) antigens for use in immunoassays for anti-HCV antibodies
JP2791418B2 (ja) * 1987-12-02 1998-08-27 株式会社ミドリ十字 異種蛋白質の製造方法、組換えdna、形質転換体
NO177065C (no) * 1988-09-26 1995-07-12 Labofina Sa Framgangsmåte for framstilling av enzymatisk aktivt humant lysozym
US5747239A (en) 1990-02-16 1998-05-05 United Biomedical, Inc. Synthetic peptides specific for the detection of antibodies to HCV, diagnosis of HCV infection and preventions thereof as vaccines
US6312889B1 (en) 1990-04-04 2001-11-06 Chiron Corporation Combinations of hepatitis c virus (HCV) antigens for use in immunoassays for anti-HCV antibodies
WO1992001800A1 (en) * 1990-07-20 1992-02-06 Chiron Corporation Method for integrative transformation of yeast using dispersed repetitive elements
CA2047792C (en) 1990-07-26 2002-07-02 Chang Y. Wang Synthetic peptides specific for the detection of antibodies to hcv, diagnosis of hcv infection and prevention thereof as vaccines
WO1993000365A2 (en) 1991-06-24 1993-01-07 Chiron Corporation Hepatitis c virus (hcv) polypeptides
AU4659993A (en) 1992-07-07 1994-01-31 Merck & Co., Inc. Vaccine comprising mixed pres1+pres2+s and core particle
EP0992580B1 (en) * 1993-11-04 2005-03-09 Innogenetics N.V. Immunodominant human T-cell epitopes of Hepatitis C virus
BR9506059A (pt) * 1994-07-29 1997-10-28 Innogenetics Nv Proteinas envelopes purificadas de virus c para uso de diagnóstico e terapêutico
ZA9610456B (en) * 1995-12-20 1997-06-20 Novo Nordisk As N-terminally extended proteins expressed in yeast
US5935824A (en) * 1996-01-31 1999-08-10 Technologene, Inc. Protein expression system
EP0946735B1 (en) * 1996-12-20 2006-02-08 Novo Nordisk A/S N-terminally extended proteins expressed in yeast
WO1999024466A2 (en) 1997-11-06 1999-05-20 Innogenetics N.V. Multi-mer peptides derived from hepatitis c virus envelope proteins for diagnostic use and vaccination purposes
JP2003525570A (ja) * 1998-01-23 2003-09-02 ノボ ノルディスク アクティーゼルスカブ 酵母において所望のポリペプチドを産生する方法
BRPI9909678B8 (pt) * 1998-04-17 2021-05-25 Fujirebio Europe N V aperfeiçoados ensaios de imunodiagnóstico usando agentes redutores
PT1090033E (pt) 1998-06-24 2005-05-31 Innogenetics Nv Particulas de proteinas de envelope do hcv: utilizacao para vacinacao
NZ518095A (en) 1999-10-27 2003-09-26 Innogenetics N Redox reversible HCV proteins with native-like conformation
RU2313363C2 (ru) 2001-01-11 2007-12-27 Иннодженетикс Н.В. Очищенные белки оболочки вируса гепатита с для диагностического и терапевтического применения
CA2443740A1 (en) * 2001-04-24 2002-10-31 Innogenetics N.V. Constructs and methods for expression of recombinant hcv envelope proteins
KR20040076869A (ko) 2001-12-18 2004-09-03 인노제네틱스 엔. 브이. 진단적 및 치료적 용도를 위한 정제된 c형 간염 바이러스외피 단백질
JP2006516955A (ja) 2002-11-08 2006-07-13 イノジェネティックス・ナムローゼ・フェンノートシャップ E1ペプチド及びns3ペプチドを含むhcvワクチン組成物

Also Published As

Publication number Publication date
JP2004536052A (ja) 2004-12-02
MXPA03009632A (es) 2004-06-30
CN1636050A (zh) 2005-07-06
EP1414942A2 (en) 2004-05-06
WO2002085932A2 (en) 2002-10-31
AR035868A1 (es) 2004-07-21
ZA200308277B (en) 2004-07-08
RU2003130955A (ru) 2005-04-20
YU84103A (sh) 2006-05-25
AR035869A1 (es) 2004-07-21
EP1381671A2 (en) 2004-01-21
MXPA03009626A (es) 2004-06-30
US20030152940A1 (en) 2003-08-14
HUP0303924A2 (hu) 2004-03-01
BR0209034A (pt) 2005-02-01
WO2002086100A2 (en) 2002-10-31
US7238356B2 (en) 2007-07-03
JP4261195B2 (ja) 2009-04-30
WO2002086100A3 (en) 2004-02-19
KR20030094359A (ko) 2003-12-11
CA2443740A1 (en) 2002-10-31
BR0209033A (pt) 2005-01-11
PL366621A1 (en) 2005-02-07
SK13142003A3 (en) 2004-11-03
US7048930B2 (en) 2006-05-23
AU2002257392B2 (en) 2007-05-10
CZ20032853A3 (cs) 2004-08-18
ZA200308274B (en) 2005-01-24
AR035867A1 (es) 2004-07-21
RU2274643C2 (ru) 2006-04-20
WO2002086101A2 (en) 2002-10-31
WO2002086101A3 (en) 2004-02-19
JP2004532029A (ja) 2004-10-21
AU2002308449B2 (en) 2008-05-29
CA2443781A1 (en) 2002-10-31
AU2002252856A1 (en) 2002-11-05
CA2444006A1 (en) 2002-10-31
US7314925B2 (en) 2008-01-01
EP1417298A2 (en) 2004-05-12
NZ529019A (en) 2004-05-28
US20030211597A1 (en) 2003-11-13
US20030108561A1 (en) 2003-06-12
KR100950104B1 (ko) 2010-03-30
WO2002085932A3 (en) 2003-03-13
NZ529324A (en) 2005-08-26
ZA200308272B (en) 2005-01-24
JP4173741B2 (ja) 2008-10-29

Similar Documents

Publication Publication Date Title
US7314925B2 (en) Constructs and methods for expression of recombinant HCV envelope proteins
AU2002308449A1 (en) Constructs and methods for expression of recombinant HCV envelope proteins
AU2002257392A1 (en) Core-glycosylated hcv envelope proteins
AU717542B2 (en) Synthetic hepatitis C genes
US20060275323A1 (en) Particles of HCV envelope proteins: use for vaccination
US6416763B1 (en) Recombinant nonstructural protein subunit vaccine against flaviviral infection
JP2002325593A (ja) キメラおよび/または増殖制限されたフラビウイルス
AU743414B2 (en) Epitopes of the protein pre-M/M of the dengue virus, synthetic peptides
CN102112601A (zh) 新的融合蛋白及其用于制备针对丙型肝炎的疫苗的用途
KR100991717B1 (ko) 바이러스에 대한 효과를 유도하는 단백질을 코딩하는키메라 사슬
US20080124763A1 (en) Constructs and methods for expression of recombinant proteins in methylotrophic yeast cells
JP2004536582A (ja) 組換え型hcvエンベロープタンパク質の発現のための構築物及び方法
JP2007289204A (ja) 組換え型hcvエンベロープタンパク質の発現のための構築物及び方法
CN1465700A (zh) 能在大肠杆菌中全长表达的丙型肝炎病毒被膜蛋白e2基因及其编码蛋白和应用
HRP20030946A2 (en) Core-glycosylated hcv envelope proteins
US20050074752A1 (en) Synthetic hepatitis C genes
MXPA99006629A (en) Epitopes of the protein pre-m/m of the dengue virus, synthetic peptides
HK1054509A (en) Recombinant envelope vaccine against flavivirus infection